Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:

NCT ID: NCT03809767 Completed - Lymphoma Clinical Trials

A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

This is a phase Ia/Ib, open-label, multiple-dose, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of CS1003 in subjects with advanced solid tumors or lymphoma.

NCT ID: NCT03804515 Terminated - Solid Tumor Clinical Trials

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Start date: June 25, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine routes of excretion and single-dose PK parameters for poziotinib in patients with solid tumors with EGFR or HER2 mutations or EGFR/HER2 overexpression/amplification.

NCT ID: NCT03802955 Completed - Solid Tumor Clinical Trials

Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

Start date: December 20, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma. ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb. It binds to the activated human T cells via a T cell receptor CD137. ADG106 administered intravenously (IV) over a period of 60-90 minutes. Primary objective: To assess safety and tolerability at increasing dose levels of single agent ADG106 in subjects with advanced or metastatic solid tumors and/or non Hodgkin lymphoma. To determine the recommended dosage and dosage regimen for further study. Secondary Objectives To characterize the pharmacokinetic (PK) profiles of ADG106. To evaluate the immunogenicity of ADG106. To evaluate the potential anti-tumor effect of ADG106. To investigate serum biomarkers related to immune regulation and cytokine releasing. Exploratory Objective: To identify the potential biomarkers of ADG106.

NCT ID: NCT03782467 Completed - Neoplasms Clinical Trials

Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

Start date: January 30, 2019
Phase: Phase 1
Study type: Interventional

The aim of the study is to investigate the safety and tolerability of ATOR-1015 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

NCT ID: NCT03781219 Recruiting - Solid Tumor Clinical Trials

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Start date: July 1, 2018
Phase: Phase 1
Study type: Interventional

This is a phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by HL-085 plus Vemurafenib treatment.

NCT ID: NCT03775525 Active, not recruiting - Breast Cancer Clinical Trials

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

GEN602
Start date: March 1, 2019
Phase: Phase 1
Study type: Interventional

This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

NCT ID: NCT03774979 Active, not recruiting - Solid Tumor Clinical Trials

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Start date: January 24, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the safety and tolerability of SHR-1701 at different dose levels. Study consists of dose-escalation part and an expansion part in subjects with metastatic or locally advanced solid tumors.

NCT ID: NCT03770494 Terminated - Solid Tumor Clinical Trials

A Study of LY3405105 in Participants With Advanced Cancer

Start date: January 31, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts phase 1a and phase 1b. Participants will only enroll in one part.

NCT ID: NCT03758781 Completed - Clinical trials for Non-Small Cell Lung Cancer

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

Start date: February 13, 2019
Phase: Phase 1
Study type: Interventional

This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors. Researchers believe that this combination will have a tolerable safety profile and will increase the response rate in comparison to Nivolumab alone.

NCT ID: NCT03758664 Recruiting - Solid Tumor Clinical Trials

Clinical Study of ICP-192 in Solid Tumors Patients

Start date: December 19, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.